The European Patent Office (EPO) has granted patent EP3265098B1, titled 'Compositions for Modulating Mecp2 Expression'. This patent, effective March 18, 2026, relates to specific compositions and their use in modulating Mecp2 expression, with potential applications in treating neurological conditions.

This grant represents a new intellectual property right in the biotechnology and pharmaceutical sectors within the designated European states. Companies operating in these areas, particularly those involved in gene therapy or neurological drug development, should review the patent claims to ensure their activities do not infringe upon this granted patent. No immediate compliance actions are required for entities not directly involved in the patented technology, but awareness is advised for those in related research and development.